Gene therapy for liver disease advanced to human testing

NEW ROCHELLE, N.Y., Dec. 30 (UPI) — Liver-directed gene therapy using adeno-associated viral, or AAV, vectors to treat diseases like hemophilia have moved on to human testing. The research, conducted by Lisa Kattenhorn and co-authors from Dimension Therapeutics in Cambridge, Mass.

Read More

Image courtesy of: AMY WALLACE